Aeon Biopharma, INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

AMEX
Ikarian Capital, LLC and Neil Shahrestani report beneficial ownership of 9.9% of AEON Biopharma, Inc. Class A common stock, including shares issuable via warrants.
AMEX
Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 5,048,027 shares, representing 9.99% of AEON Biopharma, Inc.'s Class A common stock.
AMEX
Timothy P. Lynch has filed a Schedule 13G, reporting beneficial ownership of 6,500,000 shares, representing 13.0% of AEON Biopharma's Class A Common Stock.
AMEX
Stonepine Capital Management, LLC and its affiliates have reported a 9.9% beneficial ownership in AEON Biopharma, Inc. Class A Common Stock.
AMEX
Alta Partners LLC has reported a 2.1% beneficial ownership stake in AEON Biopharma, Inc., including shares from warrants, as detailed in its latest Schedule 13G amendment.
AMEX
Alta Partners LLC has disclosed a beneficial ownership of 5.17% of AEON Biopharma, Inc.'s common stock, totaling 586,335 shares.
AMEX
Jorey Chernett has filed a Schedule 13G, revealing a significant beneficial ownership of 9.98% in AEON Biopharma, Inc., holding 1,128,500 shares of common stock.
AMEX
L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, revealing a substantial reduction in its beneficial ownership of AEON Biopharma, Inc.'s Class A Common Stock to 4.11%.
AMEX
S.H.N. Financial Investments Ltd. has reported a complete divestment of its beneficial ownership in AEON Biopharma, Inc.'s Class A Common Stock, reducing its stake from 5,400,000 shares to 0 shares.
AMEX
Polar Asset Management Partners Inc. has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in AEON Biopharma Inc.'s Class A Common Stock as of March 31, 2025.
AMEX
Alta Partners LLC has filed a Schedule 13G, reporting beneficial ownership of 6.23% of AEON Biopharma, Inc.'s common stock, indicating a substantial institutional investment.
AMEX
Dauntless Investment Group, LLC has disclosed a 9.74% passive ownership stake in AEON Biopharma, Inc., holding 108,224 common shares.
AMEX
Blue Owl Capital Holdings LP has filed an amendment to its Schedule 13G, disclosing a 3.81% beneficial ownership stake in AEON Biopharma, Inc. as of December 31, 2024.
AMEX
Polar Asset Management Partners Inc. has filed an amended Schedule 13G, revealing a 6.9% beneficial ownership stake in AEON Biopharma Inc.'s Class A ordinary shares as of December 31, 2024.
AMEX
S.H.N. Financial Investments Ltd. has reported a 6.0% beneficial ownership stake in AEON Biopharma, Inc.'s Class A Common Stock, as detailed in a recent Schedule 13G filing.
AMEX
L1 Capital Global Opportunities Master Fund, Ltd. has disclosed a 9.99% beneficial ownership stake in AEON Biopharma, Inc., comprising Class A Common Stock and warrants.
AMEX
Several investment entities and Michael Bigger disclosed a significant beneficial ownership in AEON Biopharma, Inc. as of January 6, 2025, but subsequently sold all their holdings.